Endostar

Phase 3Small molecule

Jiangsu Simcere Pharmaceutical Co., Ltd.

Endostar is one of 565 small molecule programs targeting Metastasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

564

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastasisActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

LymphomaActive, not recruiting

OsteosarcomaActive, not recruiting

Cutaneous MelanomaActive, not recruiting

NeuroblastomaActive, not recruiting

Pleural EffusionActive, not recruiting

MetastasisPhase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Lung CancerPreclinical

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

OsteosarcomaPhase 2

Active, not recruiting

Cutaneous MelanomaPhase 2

Active, not recruiting

NeuroblastomaPhase 2

Active, not recruiting

Pleural EffusionPhase 2

Active, not recruiting

Showing 10 of 22 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Endostar

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Zinecard

CChildren's Oncology Group

Preclinical

2 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Avastin

Roche

Preclinical

4 7

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 8

Lipegfilgrastim

Merck & Co.

Preclinical

1 9

Escitalopram Oxalate

TTorrent Pharmaceuticals Limited

Preclinical

1 10

Lapatinib Plus Capecitabine

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Nasopharyngeal Carcinoma

NCT06055816

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma6 trials

Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma

Completed·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT02237924·120 enrolled

Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma

Unknown status·JJiangxi Provincial Cancer Hospital·Phase 2·NCT05177237·30 enrolled

A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma

Completed·—·Phase 2·NCT02444949·75 enrolled

Show 3 more trials

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06055816·40 enrolled

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Unknown status·JJiangsu Cancer Institute & Hospital·Phase 2·NCT03932266·73 enrolled

Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 3·NCT02907710·300 enrolled

Non-Small Cell Lung Cancer4 trials

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Unknown status·NNanjing NingQi Medicine Science and Technology Co., Ltd.·Phase 4·NCT02513355·400 enrolled

Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer

Completed·SShandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd·Phase 2·NCT00708812·126 enrolled

A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)

Unknown status·SSimcere Pharmaceutical Co., Ltd·Phase 4·NCT01028729·120 enrolled

Show 1 more trial

Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)

Completed·FFudan University·Phase 2·NCT01687439·15 enrolled

Esophageal Cancer3 trials

Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT03649945·186 enrolled

Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial

Terminated·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT02749526·70 enrolled

Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients

Unknown status· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 2·NCT01368419·40 enrolled

First-line Treatment3 trials

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

Unknown status·NNanjing NingQi Medicine Science and Technology Co., Ltd.·Phase 4·NCT02513342·400 enrolled

Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

Unknown status·TThe First People's Hospital of Lianyungang·Phase 2·NCT05203276·40 enrolled

Endostar First-line Treatment of Advanced NSCLC

Unknown status·—·Phase 2·NCT03123445·150 enrolled

Small Cell Lung Cancer2 trials

A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients

Completed· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT01531790·19 enrolled

Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)

Completed·SShandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd·Phase 2·NCT00912392·138 enrolled

28 more indications

Soft Tissue Sarcoma2 trials

Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma

Unknown status·PPENG YUAN·Phase 2·NCT01812018·30 enrolled

Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma

Completed·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03121833·52 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Completed·FFudan University·Phase 2·NCT03797625·52 enrolled

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Unknown status·FFudan University·Phase 2·NCT02665702·76 enrolled

Chemotherapy2 trials

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

Unknown status·XXinqiao Hospital of Chongqing·Phase 3·NCT02579564·134 enrolled

PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

Unknown status· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT04942301·24 enrolled

Metastatic Colorectal Cancer1 trial

Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT01832948·30 enrolled

Efficacy and Safety1 trial

The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

Unknown status·FFujian Cancer Hospital·Phase 3·NCT02865304·80 enrolled

PD-1 Inhibitors1 trial

Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

Unknown status·DDong Wang·N/A·NCT04063449·170 enrolled

Pancreatic Cancer1 trial

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

Unknown status·TThe Affiliated Hospital of Xuzhou Medical University·Phase 2·NCT05298020·20 enrolled

Gastrointestinal Tumors1 trial

Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors

Unknown status·NNanjing First Hospital, Nanjing Medical University·Phase 2·NCT06301828·16 enrolled

Brain Metastases1 trial

Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases

Unknown status· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 2·NCT01410370·80 enrolled

Locally Advanced1 trial

Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT01158144·134 enrolled

Neuroblastoma1 trial

Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT02615106·60 enrolled

Gastric Cancer1 trial

Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer

Unknown status·TTang Xushan·Phase 3·NCT02008422·120 enrolled

Adjuvant Treatment1 trial

Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment

Unknown status·YYong Chen·Phase 2·NCT04699214·210 enrolled

Breast Cancer1 trial

Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT03907098·50 enrolled

Pneumonia1 trial

Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis

Completed·XXinqiao Hospital of Chongqing·Phase 2·NCT03796364·126 enrolled

Lung Adenocarcinoma1 trial

The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar

Unknown status·SSimcere Pharmaceutical Co., Ltd·Phase 2·NCT01564329·20 enrolled

Colorectal Cancer1 trial

Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT00853684·44 enrolled

Intravenous1 trial

Rh-Endostatin (Endostar®) Continuous Intravenous Infusion

Unknown status·—·Phase 2·NCT03706703·50 enrolled

NSCLC1 trial

Study of Endostar Subcutaneous Injection in NSCLC

Unknown status· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT02652234·8 enrolled

Osteosarcoma1 trial

A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma

Unknown status·SShandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd·Phase 2·NCT01002092·160 enrolled

Cervical Carcinoma1 trial

Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma

Completed·YYong Zhang,MD·Phase 2·NCT03086681·120 enrolled

Completed· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 2·NCT01327235·336 enrolled

Lung Cancer1 trial

SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer

Unknown status·PPeking University Third Hospital·N/A·NCT04274270·60 enrolled

Head and Neck1 trial

A Trial of Endostar in Patients With Carcinoma of the Head and Neck

Unknown status·CChina International Medical Foundation·Phase 2·NCT02902432·24 enrolled

Cervical Cancer1 trial

CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04121975·82 enrolled

Cutaneous Melanoma1 trial

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Unknown status·FFudan University·Phase 2·NCT05907512·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 49 trial records for Endostar. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Endostar compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Endostar. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Simcere Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Jiangsu Simcere Pharmaceutical Co., Ltd.

Endostar

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Nasopharyngeal Carcinoma6 trials

Non-Small Cell Lung Cancer4 trials

Esophageal Cancer3 trials

First-line Treatment3 trials

Small Cell Lung Cancer2 trials

Soft Tissue Sarcoma2 trials

Esophageal Squamous Cell Carcinoma2 trials

Chemotherapy2 trials

Metastatic Colorectal Cancer1 trial

Efficacy and Safety1 trial

PD-1 Inhibitors1 trial

Pancreatic Cancer1 trial

Gastrointestinal Tumors1 trial

Brain Metastases1 trial

Locally Advanced1 trial

Neuroblastoma1 trial

Gastric Cancer1 trial

Adjuvant Treatment1 trial

Breast Cancer1 trial

Pneumonia1 trial

Lung Adenocarcinoma1 trial

Colorectal Cancer1 trial

Intravenous1 trial

NSCLC1 trial

Osteosarcoma1 trial

Cervical Carcinoma1 trial

Metastasis1 trial

Lymphoma1 trial

Pleural effusion1 trial

Lung Cancer1 trial

Head and Neck1 trial

Cervical Cancer1 trial

Cutaneous Melanoma1 trial

References

Drug Info

Quick Facts

Related News